JP2008031164A - 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物 - Google Patents
高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物 Download PDFInfo
- Publication number
- JP2008031164A JP2008031164A JP2007174954A JP2007174954A JP2008031164A JP 2008031164 A JP2008031164 A JP 2008031164A JP 2007174954 A JP2007174954 A JP 2007174954A JP 2007174954 A JP2007174954 A JP 2007174954A JP 2008031164 A JP2008031164 A JP 2008031164A
- Authority
- JP
- Japan
- Prior art keywords
- loxoprofen
- pharmaceutical composition
- hyperuricemia
- disease caused
- uric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
- 201000010099 disease Diseases 0.000 title claims abstract description 35
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 229960002373 loxoprofen Drugs 0.000 claims abstract description 43
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims abstract 11
- 201000005569 Gout Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 11
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 206010007027 Calculus urinary Diseases 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 208000009911 Urinary Calculi Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 36
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 35
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 35
- 229940116269 uric acid Drugs 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229960004211 loxoprofen sodium dihydrate Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- -1 alkali metal salt Chemical class 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 239000003907 antipyretic analgesic agent Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000004503 fine granule Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000008281 urolithiasis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical class CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical class C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical class CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical class CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940024473 salicylic acid emollient and protective preparations Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007174954A JP2008031164A (ja) | 2006-07-07 | 2007-07-03 | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006188342 | 2006-07-07 | ||
| JP2007174954A JP2008031164A (ja) | 2006-07-07 | 2007-07-03 | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008031164A true JP2008031164A (ja) | 2008-02-14 |
| JP2008031164A5 JP2008031164A5 (enExample) | 2010-07-29 |
Family
ID=39120970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007174954A Pending JP2008031164A (ja) | 2006-07-07 | 2007-07-03 | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008031164A (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023039876A (ja) * | 2021-09-09 | 2023-03-22 | ＭｉＺ株式会社 | 痛風の改善および／または症状の悪化を抑制するのための組成物 |
| CN117695277A (zh) * | 2023-11-08 | 2024-03-15 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途 |
| CN117771238A (zh) * | 2023-11-08 | 2024-03-29 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物在治疗或预防代谢紊乱中的用途 |
| CN117695277B (zh) * | 2023-11-08 | 2025-12-26 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007284424A (ja) * | 2006-03-23 | 2007-11-01 | Daiichi Sankyo Healthcare Co Ltd | 循環器系疾患の予防又は治療のための医薬組成物 |
-
2007
- 2007-07-03 JP JP2007174954A patent/JP2008031164A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007284424A (ja) * | 2006-03-23 | 2007-11-01 | Daiichi Sankyo Healthcare Co Ltd | 循環器系疾患の予防又は治療のための医薬組成物 |
Non-Patent Citations (5)
| Title |
|---|
| JPN6012039780; Ｄｒｕｇｓ Ｅｘｐｔｌ． Ｃｌｉｎ． Ｒｅｓ． ＸＩＩＩ（１１）, 1987, ｐ．６８９-６９４ * |
| JPN6012039781; 肝胆膵 ４７， ４, 2003, ｐ．４６３-４７０ * |
| JPN6012039782; 日本醫事新報 ４２２３, 2005, ｐ．９４-９５ * |
| JPN6012039783; 佐藤和恵 他: 日本薬学会年会要旨集 １２０ｔｈ， ３, 2000, ｐ．８４ * |
| JPN6012050011; Ａｃｔａ Ｔｈｅｒａｐｅｕｔｉｃａ ｖｏｌ．１５, 1989, ｐ．３５５-３６１ * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023039876A (ja) * | 2021-09-09 | 2023-03-22 | ＭｉＺ株式会社 | 痛風の改善および／または症状の悪化を抑制するのための組成物 |
| CN117695277A (zh) * | 2023-11-08 | 2024-03-15 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途 |
| CN117771238A (zh) * | 2023-11-08 | 2024-03-29 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物在治疗或预防代谢紊乱中的用途 |
| WO2025098220A1 (zh) * | 2023-11-08 | 2025-05-15 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途 |
| WO2025098221A1 (zh) * | 2023-11-08 | 2025-05-15 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物在治疗或预防代谢紊乱中的用途 |
| CN117695277B (zh) * | 2023-11-08 | 2025-12-26 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途 |
| CN117771238B (zh) * | 2023-11-08 | 2025-12-26 | 合肥金科生物医药科技有限公司 | 苯丙酸类似物在治疗或预防代谢紊乱中的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210252015A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease | |
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| TW201249432A (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| JP2008013542A (ja) | 去痰又は気道杯細胞過形成抑制のための医薬組成物 | |
| JP2004161667A (ja) | 生薬配合医薬組成物 | |
| JPH02268178A (ja) | ３―ホルミルアミノ―７―メチルスルホニルアミノ―６―フェノキシ―４ｈ―１―ベンゾピラン―４―オンまたはその塩を含有する抗炎症製剤 | |
| TWI490209B (zh) | ４－甲基吡唑調配物 | |
| JP2008031164A (ja) | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物 | |
| JP2008115167A (ja) | トラネキサム酸を含有する気道杯細胞過形成抑制剤 | |
| KR20040079936A (ko) | 염기성 아미노산 ｉｉ를 함유하는 ｏ-아세틸살리실산의안정한 염 | |
| JP2017533956A (ja) | 筋肉痛を含む病態の治療のための組合せ | |
| JP2008195705A (ja) | ロキソプロフェン含有経口用組成物 | |
| JP2017171626A (ja) | プロピオン酸系非ステロイド性消炎鎮痛薬を含有した医薬組成物 | |
| JP6590822B2 (ja) | 縮合アミノジヒドロチアジン誘導体の医薬組成物 | |
| JPWO2002066030A1 (ja) | ジクロフェナクとオルノプロスチルからなる医薬組成物 | |
| JP6334088B2 (ja) | 解熱鎮痛薬組成物 | |
| JP6280303B2 (ja) | 感冒薬組成物 | |
| US20110034424A1 (en) | Method for the long term nsaid use | |
| JPWO2004017954A1 (ja) | ジクロフェナクの副作用軽減剤 | |
| CN104000814B (zh) | 一种防治痛风性关节炎的药物组合物及其用途 | |
| JP6197515B2 (ja) | 医薬組成物 | |
| WO2022051321A1 (en) | Fixed dose combinations of chs-131 and a fxr agonist | |
| WO2019098983A1 (en) | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation | |
| US20190290607A1 (en) | Administration of oral methyldopa | |
| JP6159128B2 (ja) | 抗ロタウイルス剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Effective date: 20100611 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
| A621 | Written request for application examination |
Effective date: 20100611 Free format text: JAPANESE INTERMEDIATE CODE: A621 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130711 |